# Philipp Harter

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philipp-harter/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,687 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 77 |
| i10-index | 296 |
| Last Known Institution | Gynecologic Oncology Group |
| OpenAlex ID | https://openalex.org/A5078567055 |
| ORCID iD | https://orcid.org/0000-0002-9663-5005 |
| Works | 748 |

## Researcher papers

Showing 12 of 20.

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk](https://scholariq.org/papers/common-genetic-variation-in-cellular-transport-genes-and-epithelial-ovarian/)
- [Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/endometrial-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms](https://scholariq.org/papers/a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian/)
- [Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial](https://scholariq.org/papers/surgery-in-recurrent-ovarian-cancer-the-arbeitsgemeinschaft-gynaekologische/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study](https://scholariq.org/papers/efficacy-and-safety-of-mirvetuximab-soravtansine-in-patients-with-platinum/)
- [GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer](https://scholariq.org/papers/gwas-meta-analysis-and-replication-identifies-three-new-susceptibility-loci-for/)
- [Treatment of recurrent ovarian cancer](https://scholariq.org/papers/treatment-of-recurrent-ovarian-cancer/)
- [Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial](https://scholariq.org/papers/olaparib-plus-bevacizumab-first-line-maintenance-in-ovarian-cancer-final-overall/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)

## Researcher university

- [Gynecologic Oncology Group](https://scholariq.org/institutions/gynecologic-oncology-group/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.